Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | P-BCMA-ALLO1 |
| Trade Name | |
| Synonyms | P-BCMA-ALLO 1|P-BCMA-ALLO-1 |
| Drug Descriptions |
P-BCMA-ALLO1 are allogeneic T lymphocytes engineered to express a single-domain variable heavy chain chimeric antigen receptor (VCAR) targeted against B-cell maturation antigen (BCMA), an undisclosed drug selection gene, and a caspase-based safety switch gene, which potentially inhibit tumor growth (Blood (2019) 134 (Supplement_1): 4445). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C181747 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Methotrexate + P-BCMA-ALLO1 + Rimiducid | Methotrexate P-BCMA-ALLO1 Rimiducid | 0 | 1 |
| P-BCMA-ALLO1 | P-BCMA-ALLO1 | 0 | 0 |
| P-BCMA-ALLO1 + Rimiducid | P-BCMA-ALLO1 Rimiducid | 0 | 1 |